The LAM Foundation urgently seeks safe and effective treatments, and ultimately a cure, for lymphangioleiomyomatosis (LAM) through advocacy and the funding of promising research. We are dedicated to serving the scientific, medical, and patient communities by offering information, resources, and a worldwide network of hope and support.
Founded in 1995, The LAM Foundation is the global leader in the fight against lymphangioleiomyomatosis (LAM).
LAM is a rare and progressive lung disease that primarily affects women and has no known cure. Headquartered in Cincinnati, Ohio, The LAM Foundation provides support and education for women with LAM and their families, engages doctors and scientists to continue to learn more about the disease, and raises funds for continued research. In May 2015, the FDA approved Rapamune as the first effective treatment for LAM, based on research and patient engagement supported by The LAM Foundation.
6
